Leflunomide is a Medicine belongs to Antirheumatoid group whose information about Brand can be referenced from   Book : Martindale    Page : 80   Edition : 37  

  ►   Brandname : Arava, Lara, Lefumide, Rumalef
  ►  Strength : Tablet with 10 mg.  Tablet with 20 mg.  Tablet with 100 mg. 

Reference of this Medicine for its Strength can be taken from   Book : Basic & Clinical pharmacology    Page : 656   Edition : 12  
A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : Oral
Reference :-   Book : Martindale    Page : 80   Edition : 37  

Dosing of Medicine differ in Adult & Pediatrics ↓

Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 Rheumatoid arthiritis Oral 100 mg Tablet o.d. Dose given daily for 3 days. The maintenance dose is 10 to 20 mg once daily
2 Active prosthetic arthritis Oral 100 mg Tablet o.d. Dose given daily for 3 days. The maintenance dose is 20 mg once daily

Ref :-  Book : Martindale    Page : 80   Edition : 37  

Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  
1 Rheumatic disorders 10 to < 20 kg Oral 10 mg Tablet o.d.
2 Rheumatic disorders 20-40 kg Oral 15 mg Tablet o.d.
3 Rheumatic disorders >40 kg Oral 20 mg Tablet o.d.
4 Juvenile idiopathic arthritis Oral 10 20 mg Tablet

Ref :- Book : Nelson's textbook of Pediatrics    Page : 829,838   Edition : 19   Nelson's textbook of Pediatrics    Page : 829,838   Edition : 37  
►  Side Effect : Hypertension, Gastrointestinal disturbance, Diarrhoea, Weight loss, Headache, Dizziness, leucopenia, Asthenia, Paraesthesia, Synovitis, Upper respiratory-tract infections, Alopecia, Eczema, Dry skin, Joint disorders, Hypersensitivity reactions, Stevens-Johnson syndrome, Erythema multiforme, Toxic epidermal necrolysis, Vasculitis, Hepatotoxicity, Anxiety, Peripheral neuropathy, Hypokalaemia, Mild hyperlipidaemia, Pancreatitis, Intestinal lung disease, Fatal sepsis, Renal failure
Ref :-   Book : Martindale    Page : 79   Edition : 37.  

►  Drug Interaction : Drug interaction of Leflunomide is with Myelosuppressive drugs, Hepatotoxic Drugs,  NA

  ►    Mechanism of Drug Drug Interaction :  Increased adverse effects may occur if leflunomide is given with other hepatotoxic or myelosuppressive drugs; these effects may also be seen when leflunomide treatment is followed by such drugs without a drug washout procedure. The risks of combined use with other disease-modifying antirheumatic drugs, particularly in the long term, have not been studied and such use is not advised in the UK; however, US licensed product information recommends that if longterm combined use is necessary, liver enzyme values and blood counts should be monitored monthly rather than every 6 to 8 weeks.
Ref :-   Book : Martindale    Page : 79   Edition : 37.  

►  Contraindication : Immunocompromised patients, Severe infections, Hepatic or moderate to severe renal impairment, Severe hypoproteinaemia, Bone-marrow dysplasia, Patients with a history of tuberculosis should be carefully monitored because of the possibility of reactivation of the infection, Intra-uterine devices should be used with caution during immunosuppressive treatment as there is an increased risk of infection, Live vaccines should be avoided for the same reason. Blood pressure should be monitored regularly during therapy
Ref :-   Book : Martindale    Page : 79   Edition : 37.  
  ►  Mechanism of Action :   Leflunomide undergoes rapid conversion, both in the intestine and in the plasma, to its active metabolite, A77-1726. This metabolite inhibits dihydroorotate dehydrogenase, leading to a decrease in ribonucleotide synthesis and the arrest of stimulated cells in the G 1 phase of cell growth. Consequently, leflunomide inhibits T-cell proliferation and production of autoantibodies by B cells. Secondary effects include increases of interleukin-10 receptor mRNA, decreased interleukin- 8 receptor type A mRNA, and decreased TNF-α-dependent nuclear factor kappa B (NF-κB) activation.
Ref :-   Book : Basic & Clinical pharmacology    Page : 645   Edition : 12.  

Pathway of DIETARY Product

​   ► Act.Comp / Nutrient / Food / Herb as follows :- NA

DIETARY Substance Interactions

​   ► This Medicine interact with :- NA

ContraIndication DIETARY Substance

​   ► This Medicine contraindicate with :- NA

►   Route of Elimination :   Hepatic (Metabolism), Renal, Biliary, Faecal
Ref :-   Book : Martindale    Page : 80   Edition : 37.  

►    Plasma Half-life :   Min value :-   2 weeks,    Max value :-   NA
Ref :-   Book : Martindale    Page : 80   Edition : 37.  

►    Peak Plasma Concentration :   Min value :-   1 hours,    Max value :-   24 hours.  
Ref :-   Book : Martindale    Page : 80   Edition : 37.